The combination of anti-PD-(L)1 and anti-CTLA-4 monoclonal antibodies can result in higher and longer responses in NSCLC, as observed in experimental models and clinical studies [96,97]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.